Reduction in short-acting insulin requirement accompanies improved glycemic control with basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas.
Julio
J
Rosenstock
Texas Diabetes and Endocrinology, Austin, Texas.
Thomas C
TC
Blevins
International Diabetes Center at Park Nicollet, Minneapolis, Minnesota.
Richard M
RM
Bergenstal
Profil Institute for Clinical Research Inc., Chula Vista, California.
Linda A
LA
Morrow
Lilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana, USA.
Yongming
Y
Qu
Lilly Diabetes, Eli Lilly and Company, Indianapolis, Indiana, USA.
Scott J
SJ
Jacober
D018592:Cross-Over Studies; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D038321:Glycemic Index; D006801:Humans; D007003:Hypoglycemia / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069036:Insulin Glargine / Q000627:therapeutic use*; D061268:Insulin Lispro / Q000627:therapeutic use*; D011379:Prognosis; D013997:Time Factors
D007004:Hypoglycemic Agents; D061268:Insulin Lispro; D000069036:Insulin Glargine
hypoglycemia; insulin glargine; insulin peglispro; short-acting insulin; type 1 diabetes mellitus